NCT06177574 (BIC-NOW) is a Phase 4 clinical trial of BIC/FTC/TAF in HIV Infections, sponsored by Carmen Hidalgo Tenorio.

Who is sponsoring NCT06177574?

NCT06177574 is sponsored by Carmen Hidalgo Tenorio.

What drugs are being tested in NCT06177574?

Interventions in NCT06177574: BIC/FTC/TAF.

What condition does NCT06177574 study?

NCT06177574 studies HIV Infections.

Is NCT06177574 still recruiting?

NCT06177574 is currently completed. Last updated 20 December 2023.

Last reviewed 2023-12-20 · How we verify

NCT06177574: BIC-NOW

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Bictegravir/Emtricitavine/Tenofovir Alafenamide in HIV-1 Infected naïve Patients Using Test and Treat Stategy Rapid-initiation Model of Care: BIC-NOW Clinical Trial (BIC-NOW)

Completed Phase 4 Last updated 20 December 2023

What this trial tests

Phase 4 trial testing BIC/FTC/TAF in HIV Infections in 208 participants. Completed in 30 October 2023.

Timeline

27 October 2020

Primary endpoint
30 October 2023

30 October 2023

Quick facts

Lead sponsor	Carmen Hidalgo Tenorio
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	208
Start date	27 October 2020
Primary completion	30 October 2023
Estimated completion	30 October 2023
Sites	15 locations across Spain

Drugs / interventions tested

BIC/FTC/TAF — full drug profile →

Conditions studied

HIV Infections — all drugs for HIV Infections →

Sponsor

Carmen Hidalgo Tenorio

Who can join

18 and older, any sex, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to analyze in treatment-naïve HIV patients the antiviral activity, using a test and treat strategy, in real life of BIC/FTC/TAF. Secondary, this study aims to evaluate outcomes for implementation of the evidence based test and treat strategy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial.
Hidalgo-Tenorio C, Sequera S, Vivancos MJ, Vinuesa D, et al · · 2024 · cited 12× · PMID 38574873 · DOI 10.1016/j.ijantimicag.2024.107164
Impact of bictegravir/emtricitabine/tenofovir alafenamide on health-related quality of life and economic outcomes in HIV care: Substudy of the BIC-NOW clinical trial.
Sequera-Arquelladas S, Vivancos MJ, Vinuesa D, Collado A, et al · · 2025 · cited 1× · PMID 40982450 · DOI 10.1371/journal.pone.0323167

Verify or expand the search:

Other trials of BIC/FTC/TAF

Trials testing the same drug.

NCT07266831 — A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) · Phase 2, PHASE3 · recruiting
NCT07075146 — DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity · Phase 3 · recruiting
NCT06891066 — A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunod · Phase 2 · active not recruiting
NCT05705349 — DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053) · Phase 3 · active not recruiting
NCT05630755 — A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Vir · Phase 3 · active not recruiting

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06177574 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Carmen Hidalgo Tenorio
Last refreshed: 20 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06177574.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing